BC types and therapies
| BC type | Biomarkers | Therapy |
|---|---|---|
| Luminal A-like | ERα+, PR ≥ 20%, HER2-, Ki67 < 20% | Endocrine therapy |
| Luminal B-like | ERα+, PR < 20% and/or HER2+ and/or Ki67 ≥ 20% | Endocrine therapy |
| HER2-overexpression | ERα-, PR-, HER2+ | HER2-targeted therapy |
| Basal-like | ERα-, PR-, HER2- (triple-negative) | Not responsive to endocrine or anti-HER2 therapies |
ERα+: estrogen receptor alpha positive; PR: progesterone receptor; HER2-: human epidermal growth factor receptor 2-negative; HER2+: HER2-positive; Ki67: marker of proliferation Ki-67